IRF8 and breast cancer: Likewise, Perez and colleagues reported a profile of 14 genes encoding various immune functions, which included IRF8, that were associated with a significantly improved relapse-free survival in patients with HER2+ BC treated with trastuzumab [36], supporting our data assigning IRF8 a predictive role to successful response to trastuzumab.